---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-038733"
form_type: "8-K"
ticker: "STOK"
cik: "0001623526"
company_name: "Stoke Therapeutics, Inc."
filed_at: "2023-08-07T23:59:59+00:00"
generated_at: "2026-06-12T04:20:11.369598+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Stoke Therapeutics Q2 2023 net loss $30.7M; cash $231.4M to fund operations to end of 2025

## Summary
- Net loss $30.7M ($0.69 per share) vs $24.7M ($0.63) in Q2 2022; R&D expenses $20.6M.
- Cash and marketable securities $231.4M as of June 30, 2023; expected runway to end of 2025.
- Revenue reversed $(2.5)M vs $3.2M a year ago due to $5.3M cumulative catch-up on Acadia collaboration.
- STK-001: additional data from MONARCH/ADMIRAL and OLEs expected Q1 2024 to inform Phase 3 design.
- STK-002: UK MHRA authorized Phase 1 OSPREY study for ADOA; enrollment in FALCON natural history completed (n=48).

## SEC filing metadata
- accession: 0000950170-23-038733
- form_type: 8-K
- ticker: STOK
- cik: 0001623526
- company_name: Stoke Therapeutics, Inc.
- filed_at: 2023-08-07T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1623526/000095017023038733/0000950170-23-038733-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1623526/000095017023038733/stok-20230807.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-038733
- JSON: https://secwatch.observer/filing/0000950170-23-038733.json
- Plain text: https://secwatch.observer/filing/0000950170-23-038733.txt

## Key facts
- Earnings Releases
  Stoke Therapeutics, Inc. reported financial results for the quarter ended June 30, 2023.
  - Period: the quarter ended June 30, 2023
  - Result: reported results
  source text: On August 7, 2023, Stoke Therapeutics, Inc. (the “Company”) issued a press release announcing its financial results for the quarter ended June 30, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1623526/000095017023038733/0000950170-23-038733-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.